These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31907296)

  • 1. Recurrent chromosomal rearrangements of
    Bayard Q; Caruso S; Couchy G; Rebouissou S; Bioulac Sage P; Balabaud C; Paradis V; Sturm N; de Muret A; Guettier C; Bonsang B; Copie C; Letouzé E; Calderaro J; Imbeaud S; Nault JC; Zucman-Rossi J
    Gut; 2020 Sep; 69(9):1667-1676. PubMed ID: 31907296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
    Pilati C; Zucman-Rossi J
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):499-506. PubMed ID: 26188635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
    Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
    J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.
    Pilati C; Letouzé E; Nault JC; Imbeaud S; Boulai A; Calderaro J; Poussin K; Franconi A; Couchy G; Morcrette G; Mallet M; Taouji S; Balabaud C; Terris B; Canal F; Paradis V; Scoazec JY; de Muret A; Guettier C; Bioulac-Sage P; Chevet E; Calvo F; Zucman-Rossi J
    Cancer Cell; 2014 Apr; 25(4):428-41. PubMed ID: 24735922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
    Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
    Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
    Poussin K; Pilati C; Couchy G; Calderaro J; Bioulac-Sage P; Bacq Y; Paradis V; Leteurtre E; Sturm N; Ramos J; Guettier C; Bardier-Dupas A; Boulai A; Wendum D; Selves J; Izard T; Nault JC; Zucman-Rossi J
    Oncoimmunology; 2013 Dec; 2(12):e27090. PubMed ID: 24501689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
    Calderaro J; Nault JC; Balabaud C; Couchy G; Saint-Paul MC; Azoulay D; Mehdaoui D; Luciani A; Zafrani ES; Bioulac-Sage P; Zucman-Rossi J
    Mod Pathol; 2016 Jan; 29(1):43-50. PubMed ID: 26516697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
    Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
    J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
    Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
    Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
    Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
    J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel type-1 cytokine receptor from fish involved in the Janus kinase/signal transducers and activators of transcription (Jak/STAT) signal pathway.
    Santos MD; Yasuike M; Kondo H; Hirono I; Aoki T
    Mol Immunol; 2007 Jul; 44(13):3355-63. PubMed ID: 17383728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of ROS1 rearrangement in gastric adenocarcinoma.
    Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
    Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434.
    Pastuschek J; Poetzsch J; Morales-Prieto DM; Schleußner E; Markert UR; Georgiev G
    J Reprod Immunol; 2015 Apr; 108():48-55. PubMed ID: 25817464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel
    Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.